Barclays PLC Raises Stock Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Barclays PLC increased its stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 418.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 67,222 shares of the specialty pharmaceutical company’s stock after purchasing an additional 54,257 shares during the period. Barclays PLC owned approximately 0.16% of KalVista Pharmaceuticals worth $778,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. nVerses Capital LLC bought a new position in shares of KalVista Pharmaceuticals in the 2nd quarter worth $25,000. China Universal Asset Management Co. Ltd. grew its stake in shares of KalVista Pharmaceuticals by 67.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock valued at $96,000 after buying an additional 3,328 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of KalVista Pharmaceuticals during the third quarter valued at about $126,000. SG Americas Securities LLC purchased a new position in shares of KalVista Pharmaceuticals in the third quarter worth about $153,000. Finally, Quest Partners LLC bought a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at about $175,000.

KalVista Pharmaceuticals Stock Performance

KALV stock opened at $8.47 on Wednesday. The company has a market cap of $418.57 million, a price-to-earnings ratio of -2.33 and a beta of 0.85. The business’s 50-day moving average is $9.88 and its two-hundred day moving average is $11.46. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $7.97 and a fifty-two week high of $16.88.

Insider Transactions at KalVista Pharmaceuticals

In other news, insider Paul K. Audhya sold 8,077 shares of the firm’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $74,793.02. Following the transaction, the insider now owns 94,199 shares of the company’s stock, valued at $872,282.74. This trade represents a 7.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Benjamin L. Palleiko sold 14,400 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.26, for a total value of $133,344.00. Following the transaction, the chief executive officer now owns 266,598 shares of the company’s stock, valued at approximately $2,468,697.48. This trade represents a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 32,291 shares of company stock worth $304,086 in the last quarter. Company insiders own 10.50% of the company’s stock.

Wall Street Analyst Weigh In

KALV has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. Bank of America started coverage on KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They issued a “buy” rating and a $22.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).